E Fund Management’s Immunovant IMVT Stock Holding History

E Fund Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$418K	Sell	10,843 -6,872	-39%	-$209K	0.01%	317
2026 Q1	$440K	Buy	+17,715	New	+$459K	0.01%	311
2025 Q2	$190K	Sell	11,854 -1,121	-9%	-$17K	0.01%	365
2025 Q1	$222K	Buy	12,975 +4,725	+57%	+$98.8K	0.01%	349
2024 Q4	$204K	Sell	8,250 -1,539	-16%	-$43.7K	0.01%	362
2024 Q3	$279K	Buy	9,789 +1,244	+15%	+$36.7K	0.01%	272
2024 Q2	$226K	Sell	8,545 -5,130	-38%	-$146K	0.01%	273
2024 Q1	$442K	Buy	13,675 +1,419	+12%	+$51.8K	0.03%	180
2023 Q4	$516K	Sell	12,256 -2,989	-20%	-$110K	0.03%	156
2023 Q3	$585K	Buy	15,245 +1,715	+13%	+$38.8K	0.04%	111
2023 Q2	$257K	Sell	13,530 -5,093	-27%	-$95K	0.02%	237
2023 Q1	$289K	Buy	18,623 +6,824	+58%	+$118K	0.02%	232
2022 Q4	$209K	Buy	+11,799	New	+$149K	0.02%	296
2021 Q4	–	Sell	-10,474	Closed	-$91K	–	306
2021 Q3	$91K	Buy	+10,474	New	+$94.5K	﹤0.01%	261

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

E Fund Management's IMVT Position: Q2 2026 in Review

E Fund Management reduced its Immunovant (IMVT) stake by 39% in Q2 2026, selling an estimated $209K and leaving 10,843 shares worth $418K. The position accounts for 0.01% of the portfolio, ranked #317.

E Fund Management first reported a position in IMVT in Q3 2021 and has held it in 14 quarters since. The position peaked at $585K in Q3 2023. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

E Fund Management held 10,843 shares of Immunovant worth $418K as of Q2 2026.
E Fund Management sold 6,872 Immunovant shares in Q2 2026, an estimated $209K.
Immunovant made up 0.01% of E Fund Management's portfolio in Q2 2026, its #317 holding.
E Fund Management first reported a position in Immunovant in Q3 2021 and has held it in 14 quarters since.
E Fund Management's Immunovant position peaked at $585K in Q3 2023.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.